Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / COMMON-STOCK
-
Shares outstanding
-
72.2M
-
Number of holders
-
131
-
Total 13F shares, excl. options
-
58.5M
-
Shares change
-
-5.73M
-
Total reported value, excl. options
-
$92.9M
-
Value change
-
-$20.5M
-
Put/Call ratio
-
5.38
-
Number of buys
-
59
-
Number of sells
-
-75
-
Price
-
$1.59
Significant Holders of Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) as of Q1 2025
162 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - COMMON-STOCK as of Q1 2025.
Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) has 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 58.5M shares
of 72.2M outstanding shares and own 80.95% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (14M shares), BlackRock, Inc. (4.23M shares), VANGUARD GROUP INC (3.26M shares), MILLENNIUM MANAGEMENT LLC (3.07M shares), ACADIAN ASSET MANAGEMENT LLC (2.67M shares), Decheng Capital LLC (2.02M shares), Opaleye Management Inc. (1.99M shares), Almitas Capital LLC (1.71M shares), TANG CAPITAL MANAGEMENT LLC (1.5M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.36M shares).
This table shows the top 131 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.